-374 T/A RAGE Polymorphism Is Associated with Chronic Kidney Disease Progression in Subjects Affected by Nephrocardiovascular Disease

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Baragetti, Ivano ^a   Norata, Giuseppe Danilo ^a,b,c   Sarcina, Cristina ^a   Baragetti, Andrea ^a,b   Rastelli, Francesco ^a   Buzzi, Laura ^a   Grigore, Liliana ^a,d   Garlaschelli, Katia ^a   Pozzi, Claudio ^a   Catapano, Alberico Luigi ^b,d  

^a Bassini Hospital   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d IRCCS MULTIMEDICA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CREATININE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1;

AGED; ALBUMINURIA; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

AGED; AGED, 80 AND OVER; ALLELES; ANTIGENS, NEOPLASM; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; FEMALE; GENOTYPE; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84875966762     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060089     Document Type: Article

References (51)

1. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, et al. (2003) Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 18: 1272-1280.
2. Mimic-Oka J, Simic T, Ekmescic V, Dragicevic P, (1995) Erythrocyte glutathione peroxidase and superoxide dismutase activities in different stages of chronic renal failure. Clin Nephrol 44: 44-48.
3. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK, (2003) Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int 63: 179-185.
4. Cachofeiro V, Goicochea M, de Vinuesa SG, Oubina P, Lahera V, et al. (2008) Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl: S4-9.
5. Bohlender JM, Franke S, Stein G, Wolf G, (2005) Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 289: F645-659.
6. Kirstein M, Aston C, Hintz R, Vlassara H, (1992) Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest 90: 439-446.
7. Imani F, Horii Y, Suthanthiran M, Skolnik EY, Makita Z, et al. (1993) Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling. J Exp Med 178: 2165-2172.
8. Rashid G, Benchetrit S, Fishman D, Bernheim J, (2004) Effect of advanced glycation end-products on gene expression and synthesis of TNF-alpha and endothelial nitric oxide synthase by endothelial cells. Kidney Int 66: 1099-1106.
9. Bucala R, Tracey KJ, Cerami A, (1991) Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 87: 432-438.
10. Yamagishi S, Nakamura K, Matsui T, Noda Y, Imaizumi T, (2008) Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr Pharm Des 14: 487-495.
11. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA, (2003) The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42: 1149-1160.
12. Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, et al. (2005) Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25: 1032-1037.
13. Ramasamy R, Yan SF, Schmidt AM, (2009) RAGE: therapeutic target and biomarker of the inflammatory response-the evidence mounts. J Leukoc Biol 86: 505-512.
14. Grossin N, Wautier MP, Meas T, Guillausseau PJ, Massin P, et al. (2008) Severity of diabetic microvascular complications is associated with a low soluble RAGE level. Diabetes Metab 34: 392-395.
15. Yan SF, Ramasamy R, Schmidt AM, (2010) The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 106: 842-853.
16. Hudson BI, Stickland MH, Futers TS, Grant PJ, (2001) Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 50: 1505-1511.
17. Pettersson-Fernholm K, Forsblom C, Hudson BI, Perola M, Grant PJ, et al. (2003) The functional-374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes 52: 891-894.
18. Falcone C, Geroldi D, Buzzi MP, Emanuele E, Yilmaz Y, et al. (2008) The-374T/A RAGE polymorphism protects against future cardiac events in nondiabetic patients with coronary artery disease. Arch Med Res 39: 320-325.
19. Kucukhuseyin O, Aydogan HY, Isbir CS, Isbir T, (2009) Associations of-374T/A polymorphism of receptor for advanced glycation end products (RAGE) gene in Turkish diabetic and non-diabetic patients with coronary artery disease. In Vivo 23: 949-954.
20. Kirbis J, Milutinovic A, Steblovnik K, Teran N, Terzic R, et al. (2004) The-429 T/C and-374 T/A gene polymorphisms of the receptor of advanced glycation end products gene (RAGE) are not risk factors for coronary artery disease in Slovene population with type 2 diabetes. Coll Antropol 28: 611-616.
21. dos Santos KG, Canani LH, Gross JL, Tschiedel B, Pires Souto KE, et al. (2005) The-374A allele of the receptor for advanced glycation end products gene is associated with a decreased risk of ischemic heart disease in African-Brazilians with type 2 diabetes. Mol Genet Metab 85: 149-156.
22. Lindholm E, Bakhtadze E, Sjogren M, Cilio CM, Agardh E, et al. (2006) The-374 T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients. Diabetologia 49: 2745-2755.
23. Abdel-Azeez HA, El-Okely AM, (2009) Association of the receptor for advanced glycation end products (RAGE)-374 T/A gene polymorphism and circulating soluble RAGE with nephropathy in type 1 diabetic patients. Egypt J Immunol 16: 95-106.
24. Goolsby MJ, (2002) National Kidney Foundation Guidelines for chronic kidney disease: evaluation, classification, and stratification. J Am Acad Nurse Pract 14: 238-242.
25. Norata GD, Baragetti I, Raselli S, Stucchi A, Garlaschelli K, et al. (2010) Plasma adiponectin levels in chronic kidney disease patients: relation with molecular inflammatory profile and metabolic status. Nutr Metab Cardiovasc Dis 20: 56-63.
26. Norata GD, Garlaschelli K, Grigore L, Raselli S, Tramontana S, et al. (2010) Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Atherosclerosis 208: 177-182.
27. Norata GD, Raselli S, Grigore L, Garlaschelli K, Dozio E, et al. (2007) Leptin:adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke 38: 2844-2846.
28. Predazzi IM, Norata GD, Vecchione L, Garlaschelli K, Amati F, et al. (2012) Association between OLR1 K167N SNP and Intima Media Thickness of the Common Carotid Artery in the General Population. PLoS One 7: e31086.
29. Norata GD, Garlaschelli K, Ongari M, Raselli S, Grigore L, et al. (2006) Effects of fractalkine receptor variants on common carotid artery intima-media thickness. Stroke 37: 1558-1561.
30. Ammirati E, Cianflone D, Banfi M, Vecchio V, Palini A, et al. (2010) Circulating CD4+CD25hiCD127lo Regulatory T-Cell Levels Do Not Reflect the Extent or Severity of Carotid and Coronary Atherosclerosis. Arterioscler Thromb Vasc Biol 30: 1832-1841.
31. Norata GD, Grigore L, Raselli S, Redaelli L, Hamsten A, et al. (2007) Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis 193: 321-327.
32. Norata GD, Raselli S, Grigore L, Garlaschelli K, Vianello D, et al. (2009) Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells. Atherosclerosis 206: 556-562.
33. Norata GD, Garlaschelli K, Grigore L, Tibolla G, Raselli S, et al. (2009) Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr Metab Cardiovasc Dis 19: 129-134.
34. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, et al. (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57: 450-458.
35. Ammirati E, Cianflone D, Vecchio V, Banfi M, Vermi AC, et al. (2012) Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models. J Am Heart Assoc 1: 27-41.
36. Wendelhag I, Wiklund O, Wikstrand J, (1993) Atherosclerotic changes in the femoral and carotid arteries in familial hypercholesterolemia. Ultrasonographic assessment of intima-media thickness and plaque occurrence. Arterioscler Thromb 13: 1404-1411.
37. Kang P, Tian C, Jia C, (2012) Association of RAGE gene polymorphisms with type 2 diabetes mellitus, diabetic retinopathy and diabetic nephropathy. Gene 500: 1-9.
38. Kalea AZ, Schmidt AM, Hudson BI, (2011) Alternative splicing of RAGE: roles in biology and disease. Front Biosci 16: 2756-2770.
39. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, et al. (2003) RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162: 1123-1137.
40. Ehlermann P, Eggers K, Bierhaus A, Most P, Weichenhan D, et al. (2006) Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol 5: 6.
41. Yamagishi S, Fukami K, Ueda S, Okuda S, (2007) Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets 8: 952-959.
42. Fukami K, Ueda S, Yamagishi S, Kato S, Inagaki Y, et al. (2004) AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 66: 2137-2147.
43. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, et al. (2003) Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Kidney Int 63: 464-473.
44. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, et al. (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 97: 8015-8020.
45. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, et al. (1994) Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 91: 11704-11708.
46. Norata GD, Callegari E, Marchesi M, Chiesa G, Eriksson P, et al. (2005) High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells. Circulation 111: 2805-2811.
47. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, et al. (1994) Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A 91: 9436-9440.
48. Bianchi S, Bigazzi R, Campese VM, (2010) Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. Am J Kidney Dis 55: 671-681.
49. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, et al. (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377: 2181-2192.
50. Burton JO, Gray LJ, Webb DR, Davies MJ, Khunti K, et al. (2012) Association of anthropometric obesity measures with chronic kidney disease risk in a non-diabetic patient population. Nephrol Dial Transplant 27: 1860-1866.
51. Reaich D, Price SR, England BK, Mitch WE, (1995) Mechanisms causing muscle loss in chronic renal failure. Am J Kidney Dis 26: 242-247.